Training and sharing knowledge in immunoengineering
Tech-Train-Dissem Core
['FUNDING_OTHER'] · JOHNS HOPKINS UNIVERSITY · NIH-11134633
This study is all about helping scientists and engineers work together to improve treatments for cancer by sharing new ideas and skills in a field called immunoengineering, which could eventually lead to better therapies for patients like you.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11134633 on ClinicalTrials.gov |
What this research studies
This research focuses on bridging the gap between engineering and immunology by providing training and resources in the field of immunoengineering. It aims to disseminate knowledge, tools, and techniques to researchers and practitioners through workshops, seminars, and collaborative initiatives. Patients may benefit indirectly as advancements in immunoengineering could lead to improved cancer immunotherapy treatments. The program also includes innovative educational initiatives to foster collaboration and innovation in this emerging field.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research are patients with cancer who may be treated with advanced immunotherapy techniques.
Not a fit: Patients who are not undergoing cancer treatment or do not have access to immunotherapy may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could enhance the development of more effective cancer immunotherapy treatments.
How similar studies have performed: Other research initiatives in immunoengineering have shown promise in improving cancer treatment outcomes, indicating that this approach is both relevant and potentially impactful.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SUNSHINE, JOEL CHAIM — JOHNS HOPKINS UNIVERSITY
- Study coordinator: SUNSHINE, JOEL CHAIM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer immunotherapy, cancer immunotherapy